Real‐world blood examination screening data before initiation of biologics for psoriasis patients. Issue 5 (22nd February 2022)

• Record Type: Journal Article
• Authors: Ozaki, Saeko; Ichiyama, Susumu; Ito, Michiko; Hoashi, Toshihiko; Kanda, Naoko; Saeki, Hidehisa
• Is Part Of: Journal of dermatology. Volume 49:Issue 5(2022)
• Page Start: 534
• Page End: 538
• Publication Date: 2022-02-22
• Subjects: biologics -- blood examination -- psoriasis -- real‐world -- screening; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.16333
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: Psoriasis is a chronic immune‐mediated inflammatory skin disease characterized by hyperproliferation of epidermal keratinocytes. Biologics have been available for the treatment of patients with refractory psoriasis since 2010 in Japan, and as of December 2021, 10 biologics were available. The Biologics Review Committee of the Japanese Dermatological Association for Psoriasis recommends blood examination tests for antinuclear antibodies (ANA), Krebs von den Lugen (KL)‐6, hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (HBsAb), hepatitis B core antibodies (HBcAb), hepatitis C virus (HCV) antibodies, HIV antibodies, human T‐cell leukemia virus (HTLV)‐1 antibodies, β‐D‐glucan, and the T‐cell spot (T‐SPOT) test before initiation of biologics at screening. In this study, we evaluated the use of biologics for 127 psoriasis patients and the blood examination screening data before initiation of biologics in the real‐world setting. Tumor necrosis factor inhibitors, interleukin (IL)‐17 inhibitors and IL‐23 inhibitors were initiated for 54 (42.5%), 36 (28.3%), and 37 (29.1%) patients, respectively. The numbers of patients positive for ANA, HBsAg, HBsAb, HBcAb, HCV antibody, HIV antibody, HTLV‐1 antibody, and T‐SPOT were 27 (21.3%), 0 (0%), 22 (17.3%), 20 (15.7%), three (2.4%), zero (0%), one (0.8%), and 4 (3.1%), respectively. The numbers of patients whose KL‐6 and β‐D‐glucan levels were higher than the reference values were seven (5.5%) and seven (5.5%), respectively. In the real‐world setting, it is sometimes unavoidable to use biologics for those patients with abnormal data although careful monitoring is necessary.